The company’s Microbial Fermentation and Complex Chemistry Site will open in December.
Canadian CDMO BioVectra Inc. announced their total manufacturing capacity will increase by 40%, with the addition of a fourth new cGMP facility. The late-stage to commercial-scale microbial fermentation and complex chemistry facility will be located in Windsor, Nova Scotia, offering convenience to customers located in the Northeast.
The $30 million investment equips the new 50,000 square-foot facility with 40,000 liters of fermentation capacity, downstream processing equipment and new preclinical fermentation and potent chemistry suites. The new facility expansion, the company explains, increases their value to potential clients by offering dual-site risk mitigation.
“This expansion helps BioVectra keep up with the growing demand for our products, while also meeting an underserved need for large-scale microbial fermentation in North America,” commented Heather Delage, Vice President of Business Development.
Oliver Technow, BioVectra’s President reinforced this, adding, “The investment strengthens our unique position in the very competitive global marketplace, enabling us to offer new and existing clients range of scale throughout the entire lifecycle of a product.”
The company’s three existing facilities, as well as their headquarters are located in Charlottetown, Prince Edward Island. A wholly owned subsidiary of Mallinckrodt Pharmaceuticals, BioVectra has over 45 years of experience in the areas of Microbial Fermentation, Complex Chemistry, High-Potency APIs, Process & Analytical Development, and Drug Development.
Biovectra Inc.President Oliver Technow